Strip of 10 UNITS
Old MRP ₹135
MRP ₹126.56
₹101.25
₹12.66/UNITS
100% genuine medicines
Safe & secure payments
15 days Easy returns
Prescription required for this medicine
Store Below 30o C
Glucobit GM 1 MG Tablet 10 is used to manage type 2 diabetes mellitus. It a triple-combination of oral antidiabetic agent: glimepiride, metformin, and voglibose. It works through a triple mechanism, reducing glucose absorption, stimulating insulin release, and improving insulin sensitivity, to control blood sugar levels effectively.
Glucobit GM 1 MG Tablet 10 is used to treat Type 2 Diabetes by controlling high blood sugar levels. It works by improving insulin sensitivity and reducing glucose production in the body.
Swallow the tablet whole with a glass of water.
Do not crush, chew, or cut the tablet.
Do not take more than the dose recommended by your doctor.
Always consult your doctor before stopping this medicine.
Glucobit GM 1 MG Tablet 10 is taken orally.
The Glucobit GM 1 MG Tablet 10 may cause upper respiratory tract infections, diarrhoea, nausea, vomiting, abdominal pain, dizziness, flatulence, headache, and low blood glucose (hypoglycaemia). Contact your healthcare provider if these symptoms worsen.
Most side effects are temporary, usually mild, and resolve upon stopping the use of Glucobit GM 1 MG Tablet 10. However, if you experience any serious side effects or worsening of any of the symptoms, please consult your doctor.
Here are some useful tips for handling common side effects:
Diarrhoea: Try taking Glucobit GM 1 MG Tablet 10 with food or milk.
Hypoglycaemia: If you experience low blood sugar levels, consider having a small snack or drink containing sugar.
Glucobit GM 1 MG Tablet 10 consists of three active ingredients:
Glimepiride (1 mg): As a sulfonylurea, it stimulates insulin secretion from functioning pancreatic beta cells by binding to their surface receptors. This activity promotes an increase in intracellular calcium that triggers insulin secretion.
Metformin (500 mg): This biguanide reduces glucose production by the liver, decreases intestinal absorption of glucose, and improves insulin sensitivity by enhancing peripheral glucose absorption and utilisation. It activates a liver enzyme known as AMPK to regulate these processes.
Voglibose (0.2 mg): It is an alpha-glucosidase inhibitor that slows down carbohydrate digestion and absorption within the intestines. This action helps reduce post-meal glucose and insulin levels.
Caution is advised while taking Glucobit GM 1 MG Tablet 10 if you are pregnant. It is best to consult your doctor before using this medicine.
Glucobit GM 1 MG Tablet 10 is secreted in human milk. Proceed with caution and take the medicine only after discussing it with your doctor.
Alcohol consumption can increase the risk of lactic acidosis and hypoglycaemia when taking Glucobit GM 1 MG Tablet 10. It is advisable to limit your alcohol intake while on this medication.
Avoid using Glucobit GM 1 MG Tablet 10 if you have liver impairment, as it may increase the risk of lactic acidosis. If you have any liver issues, consult your doctor before starting this medication.
Glucobit GM 1 MG Tablet 10 is not recommended for severe kidney disease or impairment. If you have a history of kidney problems, consult your doctor before starting this medicine.
There are no specific precautions regarding driving or operating heavy machinery while taking Glucobit GM 1 MG Tablet 10; however, be aware that hypoglycaemia (low blood sugar) can affect your ability to perform these tasks safely.
If you have a history of serious hypersensitivity reaction to glimepiride, metformin, or voglibose, avoid using Glucobit GM 1 MG Tablet 10. Consult your doctor for alternatives.
Glucobit GM 1 MG Tablet 10 is not recommended for use in children under the age of 18 without medical supervision. Always consult a doctor before giving any medication to a child.
For older patients, caution is advised due to their increased sensitivity to the hypoglycaemic effects of glimepiride. Kidney function should also be assessed more frequently in these patients before they take Glucobit GM 1 MG Tablet 10.
Glucobit GM 1 MG Tablet 10 interacts with the following medicines:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs like ibuprofen and naproxen can amplify the blood sugar-lowering effect of glimepiride in Glucobit GM 1 MG Tablet 10.
Cardiac glycosides: Medicines like digoxin may have altered absorption due to voglibose in Glucobit GM 1 MG Tablet 10.
Thyroid medications: Medications used to treat hypothyroidism, like levothyroxine and liothyronine, can decrease the effectiveness of glimepiride in Glucobit GM 1 MG Tablet 10.
Certain foods can interact with Glucobit GM 1 MG Tablet 10.
High-fibre foods: If you have a diet rich in fibre, this may affect the absorption of metformin in your body.
Glucobit GM 1 MG Tablet 10 interacts with the following diseases:
Kidney disease: Patients with moderate to severe kidney disease should avoid this medicine, as it can increase the risk of lactic acidosis.
Liver disease: Patients with liver disease should not use this medicine, as it might worsen their condition.
The daily dose of Glucobit GM 1 MG Tablet 10 should be as advised by your doctor, considering the severity of your condition and your response to the medicine. Strictly follow the prescribed dosage and avoid exceeding it without your doctor's approval.
Overdosing on Glucobit GM 1 MG Tablet 10 may result in symptoms such as nausea, abdominal pain, and fatigue. If you experience these or other symptoms, consult your doctor for advice.
If you miss a dose of Glucobit GM 1 MG Tablet 10, take it as soon as you remember. If it's nearly time for the next dose, skip the missed one and continue with your regular schedule. Never increase your dose without consulting your doctor.
Maintain an ideal storage environment for Glucobit GM 1 MG Tablet 10 at room temperature.
Protect the medicine from excessive heat, moisture, and direct sunlight.
Ensure the medicine is securely stored out of reach of children.
Be mindful of the expiration date on the packaging and use the medicine before this date.
Incorporate a balanced diet rich in fibre and low in sugar to manage your blood glucose levels.
Regular physical activity, such as walking or yoga, can help improve insulin sensitivity and support the effectiveness of this medication.
| Available Dosage Types | Tablet |
| Habit Forming | No |
| Ailment | Type 2 Diabetes Mellitus |
| Drug Category | Sulfonylurea, Biguanide, Alpha-glucosidase Inhibitor |
| Therapeutic Category | Antidiabetic |
Glucobit GM 1 MG Tablet 10 is used to manage blood sugar levels in adults with type 2 diabetes, along with diet and exercise.
The medicine's three ingredients work together to lower blood glucose levels by enhancing insulin secretion, reducing glucose production, and slowing carbohydrate absorption.
Do not take Glucobit GM 1 MG Tablet 10 if you have moderate to severe kidney impairment. If you have a history of kidney issues, always inform your doctor beforehand.
Women who are pregnant or breastfeeding should exercise caution before taking this medicine. Take it only if your doctor says the benefits outweigh the potential risks.
Common side effects include upper respiratory tract infection, diarrhoea, nausea, vomiting, abdominal pain, dizziness, headache, hypoglycaemia, and flatulence.
Yes, metformin may reduce vitamin B12 levels. You should check your haematological parameters regularly if you are taking Glucobit GM 1 MG Tablet 10.
Overdose can lead to hypoglycaemia from glimepiride and lactic acidosis from metformin. Seek immediate medical attention in such cases.
Check out Editorial Policy
U.S. Food and Drug Administration. (2013, Oct). Amaryl (glimepiride) tablet label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020496s027lbl.pdf
U.S. Food and Drug Administration. (2017, Apr). Glucophage (metformin) tablet label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 3476, Glimepiride. https://pubchem.ncbi.nlm.nih.gov/compound/Glimepiride
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 4091, Metformin. https://pubchem.ncbi.nlm.nih.gov/compound/Metformin
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 444020, Voglibose. https://pubchem.ncbi.nlm.nih.gov/compound/Voglibose
Dabhi, A. S., Bhatt, N. R., & Shah, M. J. (2013). Voglibose: an alpha glucosidase inhibitor. Journal of clinical and diagnostic research: JCDR, 7(12), 3023–3027. https://doi.org/10.7860/JCDR/2013/6373.3838
Parmar, N., Gupta, A. K., Jhaveri, K., A, B., Chhaya, G., Kansara, S., Nair, R., & Korukonda, K. R. (2024). Real-World Assessment of Personalized Approach With Voglibose Fixed-Dose Combination in Type 2 Diabetes Mellitus. Cureus, 16(4), e57494. https://doi.org/10.7759/cureus.57494
We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.
50.1% CHEAPER
8919 users bought this instead
Read More
...View more
...View more
...View more
Company
About UsHealth ArticleHealth StoriesHealth LibraryDiseases & Health ConditionsAyurvedaAll MedicinesAll BrandsNeed HelpFAQSecuritySubscribe
Registered Office Address
Grievance Officer
Download Truemeds
Contact Us
Our customer representative team is available 7 days a week from 9 am - 9 pm.
v4.8.2
2025 - Truemeds | All rights reserved. Our content is for informational purposes only. See additional information.
Our Payment Partners
Composition
